Aetna · Fostamatinib ITP · US health-plan appeal rights

Fostamatinib ITP denied as duplicate or overlapping therapy by Aetna?

Q: How long do I have to appeal a Aetna Fostamatinib ITP denial?

Internal appeal window: Typically 180 days from the denial date. External review window: Typically 60–120 days after the final internal denial. The clock starts from the date on the denial letter.

If two medications appear duplicative on paper but serve different clinical purposes (e.g., short-acting vs long-acting), the appeal needs to spell out the clinical rationale for both.

By Michael John Ryan, Founder & Privacy Officer, DenialHelp, LLC

Last reviewed 2026-05-11

Policy data current as of 2026-04-26

US health-plan appeal rights

Cite: Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules

Most US health plans are required by federal law to give you both an internal appeal (where the insurer reconsiders) and an external review (where an independent reviewer decides). The exact timelines and processes depend on what kind of plan you have — marketplace / employer group, self-funded, Medicare Advantage, or Medicaid MCO — but in every case there's a window after the denial during which you have the right to fight it.

Internal appeal window

Typically 180 days from the denial date

External review window

Typically 60–120 days after the final internal denial

What Aetna typically requires

Aetna's specific coverage criteria for fostamatinib itp are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

Source policy: Aetna CPB on Tavalisse (Fostamatinib) for Chronic ITP

The Aetna angle on Fostamatinib ITP

## Why Aetna Denied Fostamatinib (for ITP) as Duplicate Therapy

Aetna's duplicate-therapy denial for fostamatinib (Tavalisse) in immune thrombocytopenia (ITP) generally means the plan identified another ITP treatment — such as a thrombopoietin receptor agonist (TPO-RA), rituximab, or another agent — as active on your record and concluded that fostamatinib covers the same clinical purpose. This is a particularly contestable denial because fostamatinib has a distinct mechanism of action (spleen tyrosine kinase inhibition) compared to all other approved ITP therapies, meaning it is not mechanistically duplicative.

## Federal Appeal Framework

Internal appeal: File within the deadline stated in the denial letter (typically 180 days for Aetna commercial plans). Aetna must respond within 30 days for non-urgent prospective requests.
External review (ACA §2719 / ERISA §503): After an internal denial, request independent external review within approximately 4 months. An IRO with hematology expertise reviews the mechanistic-duplication question independently. Expedited review (72 hours) is available when platelet counts or bleeding risk make delay a serious health concern.

## Documentation to Gather

1. Prior ITP treatment history: A complete, dated list of every ITP therapy you have received — drug, start date, end date, response achieved (platelet counts over time), and documented reason for stopping or switching. This establishes that prior agents are not currently duplicating fostamatinib's role. 2. Mechanistic distinction letter: A letter from the treating hematologist explaining that fostamatinib's mechanism is not replicated by any agent currently active on your record, and why your ITP has not been adequately controlled by prior or concurrent therapies. 3. Current disease severity: Recent platelet count history, bleeding episode documentation, and physician assessment of clinical urgency. 4. Applicable guideline reference: A reference to the relevant guideline body (e.g., the American Society of Hematology ITP guidelines) supporting use of fostamatinib in patients who have not responded to or are not candidates for other approved therapies.

## Criteria-Mapping Structure

Obtain Aetna's published clinical policy bulletin for fostamatinib and the FDA-approved prescribing label. List every coverage criterion and every exclusion. For each requirement, document the specific chart entry that satisfies it. For the duplication exclusion specifically, provide a side-by-side comparison of the mechanism of the allegedly duplicating drug versus fostamatinib's SYK-inhibition pathway, supported by your hematologist's letter.

Next steps

Find the date on the denial letter — your appeal window starts there.
Read your plan's Summary of Benefits and Coverage (SBC) for the specific deadlines.
Request the insurer's claim file in writing — they must provide it.
Submit your appeal in writing with new clinical evidence and a physician statement.

Get the letter drafted

DenialHelp drafts your appeal in 5 minutes — $40 list price, $30 for your first letter (use code SEO25). We cite the federal regs and the specific clinical evidence your plan responds to. Your physician signs and sends.

Start my appeal — $30 with code SEO25 →

Related appeal guides

Other Aetna appeals

Other denial reasons for Aetna Fostamatinib ITP

denied as not medically necessary denied for failing step therapy denied as non-formulary denied for missing prior authorization denied as experimental or investigational

This guide describes general US federal appeal rights based on Most US health plans have appeal rights under either the ACA, ERISA, or Medicare/Medicaid rules. Your specific plan documents (Summary of Benefits and Coverage, Evidence of Coverage) override anything here. DenialHelp is not your lawyer and not your physician — we draft appeal letters that your physician signs. Outcomes depend on your insurer's decision and factors outside our control. Reviewed by Michael John Ryan on 2026-05-11. Editorial standards: denialhelp.com/authors.